A top U.S. regulator is discrediting research published a year ago that found impurities in dozens of generic heart drugs made overseas, saying the investigators contaminated the samples during their testing.
Valinda Parrish talks to her 60- year-old husband like a doting mother speaks to a child. “I am going to go outside for a little bit,” she tells him. “Use your horn if you need me.”
U.S. regulators plan an extensive study of blood-pressure drugs that generate almost 40 million prescriptions a year, after receiving thousands of complaints from doctors and patients.
The Food and Drug Administration hasn’t approved Ranbaxy Laboratories Ltd.’s generic version of Pfizer Inc.’s $10.7 billion Lipitor cholesterol pill, Sandy Walsh, a spokeswoman for the agency, said.
Generic drugs that make up almost 80 percent of U.S. prescriptions are being tested in the first widespread safety and quality evaluation run by the Food and Drug Administration.
Pfizer Inc.’s $10.7 billion cholesterol pill Lipitor gained a rival today after Ranbaxy Laboratories Ltd. was cleared by U.S. regulators to sell copies of the drug.
"The warnings on the drugs do not say not to treat depression."
- Sandy Walsh on Jun 18, 2014